A Global Call to Action for FH

A Global Call to Action – Reducing the Clinical and Public Health Burden of Familial Hypercholesterolemia

No Comments

Healthcare systems around the world have failed to rescue individuals born with Familial Hypercholesterolemia (FH), even though we have had life-saving therapies for the last 34 years. Without the societal commitment to screen, diagnose, and manage FH, the opportunity to prevent heart disease and … Read More →


News Alert - FDA Approves Evinacumab

ICER Virtual Public Meeting

ICER Report on Treatments for High Cholesterol – FH Foundation to Comment at Public Meeting February 5

No Comments

The Institute for Clinical and Economic Review (ICER) – an organization that produces reports that analyze the cost effectiveness of drugs and other medical services – has highlighted the improved cost-effectiveness of high cholesterol treatments inclisiran and bempedoic acid in patients who have … Read More →


FDA Listening Session on HoFH

photo of people raising hand to advocate

First Iraqi Advocacy Group

Capitol Hill

Community in Action


Illustration relating to Costs and Health Insurance

Why are FH patients paying a higher price for PCSK9 inhibitor treatment when a lower price is available, and what can we do about it?

2 Comments

Affordable prescription drugs are necessary so individuals can benefit from advances in medicine to treat conditions such as familial hypercholesterolemia. Medical research and innovation make it possible to actually prevent or delay heart disease in people born with FH. All it takes is early diagnosis … Read More →